Pharmacometric analysis to assess the risk–benefit profile of nintedanib

Exposure-safety analyses are often a great complement to exposure-response analyses in order to drive key MIDD decisions such as therapeutic dose selection. In this example, our colleague Celine Sarr and collaborators from Boehringer Ingelheim demonstrated the power of such analyses for nintedanib, looking into liver enzymes elevation and diarrhea. Read the publication here and see about the exposure-response analysis here.